Macro International touches roof on entering into contrast media business
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Macro International is currently trading at its upper limit of Rs. 27.70, up by 1.31 points or 4.96% from its previous closing of Rs. 26.39 on the BSE.
The scrip opened at Rs. 27.70 and has touched a high and low of Rs. 27.70 and Rs. 27.70 respectively. So far 6390 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 32.62 on 15-May-2023 and a 52 week low of Rs. 21.50 on 29-Aug-2022.
Last one week high and low of the scrip stood at Rs. 28.07 and Rs. 25.10 respectively. The current market cap of the company is Rs. 11.01 crore.
The promoters holding in the company stood at 61.13%, while Non-Institutions held 38.87% stake in the company.
Macro International has entered into the ‘Contrast media’ business, focusing on the manufacturing and distribution of loperamide USP in bulk drug form. Contrast media is an indispensable component of critical care segment, particularly in radiology which plays a pivotal role in diagnosing life-threatening illnesses and treating critically ill patients.
Iopromide is a non-ionic, water-soluble, tri-iodinated x-ray contrast agent designed for intravascular administration. Also known as Contrast Media, it finds common application in radiographic studies such as intravenous programs, brain computer tomography (CT), and CT pulmonary angiograms (CTPAs). Iopromide serves as a contrast agent by enhancing the visibility of blood vessels, enabling radiographic visualization of internal structures until hem dilution occurs.
Macro International has been the leading manufacturer and supplier of neoprene sheets, neoprene rolls, and neoprene products in North America. With over three decades of company history and continued excellence.
